Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Novo Nordisk is doing exceptionally well in the ... which is a long-acting growth hormone. Thanks to less frequent injections and the fact that it is not inferior to Norditropin, Sogroya is ...

Novo Nordisk has ... version of parathyroid hormone (PTH), which is for the treatment of hypoparathyroidism in adults, and Skytrofa (lonapegsomatropin), a long-acting growth hormone for children ...

A next-generation Novo Nordisk metabolic disorder drug led to ... Cagrilintide, a long-acting version of the hormone amylin, activates the amylin receptor, which plays a role in regulating blood ...

Novo Nordisk A/S ... rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.